Advertisement

Table of Contents: May 2005

COVER

Medication Time at Rosemount.

Image Credit: Glenn Brady (glenox [at] byrononline.net)
Issue Image

This painting was done in 1992 or 1993. It was just after I had left Rosemount psychiatry ward, which was the first time I had been in hospital. It was an eye-opener. Being in hospital was everything that you expect it to be, but then nothing like that at all. The end of the line—I had nowhere else to go.

The painting itself was a tough one. Even though it looks fairly simple, to get it to that stage, the colours and shapes, was quite a chore. Every morning and night was medication time and all the patients in our ward would line up outside of a small window through which a nurse would dispense the various pills. At first I tried to paint the picture in the colours of the scene itself (a faint lemon colour)—it didn't work. I tried many different background colours for days until I thought about it—instead of painting the scene, paint what it felt like the mood of it.

In this issue of PLoS Medicine, Dr. John McGrath and colleagues publish the results of a systematic review of the prevalence of schizophrenia. He and the staff of the University of Queensland Park Centre for Mental Health use paintings such as this one by Glenn Brady to teach students about the person behind the disorder. McGrath writes:

Glenn's painting provides a vivid glimpse into psychiatric care early last decade. Over the last three decades, many developed countries have shifted the care of people with psychotic disorders from inpatient settings to the community. However, we still have a long way to go. Despite optimal treatment (medication, rehabilitation, and disability support), many people with schizophrenia still have persisting disability. Paintings can communicate the pain and suffering associated with serious mental illness better than textbooks. Glenns work inspires our staff to research ways to improve services for those with psychotic disorders, and also to unravel the genetic and nongenetic factors that cause schizophrenia.

Editorial

Essays

Is Evidence-Based Medicine Relevant to the Developing World?

Paul Chinnock, Nandi Siegfried, Mike Clarke

Perspectives

Health in Action

Policy Forums

Nanotechnology and the Developing World

Fabio Salamanca-Buentello, Deepa L Persad, Erin B Court, Douglas K Martin, Abdallah S Daar, Peter A Singer

Vaccine Policy in India

Yennapu Madhavi

Research in Translation

The Development of Vaginal Microbicides for the Prevention of HIV Transmission

Jonathan Weber, Kamal Desai, Janet Darbyshire , on behalf of the Microbicides Development Programme

Learning Forum

Case Report

Autoimmune Thyroid Disease with Fluctuating Thyroid Function

Ali S Alzahrani, Saleh Aldasouqi, Suzan Abdel Salam, Ali Sultan

Research Articles

Rethinking the “Diseases of Affluence” Paradigm: Global Patterns of Nutritional Risks in Relation to Economic Development

Majid Ezzati, Stephen Vander Hoorn, Carlene M. M Lawes, Rachel Leach, W. Philip T James, Alan D Lopez, Anthony Rodgers, Christopher J. L Murray

A Systematic Review of the Prevalence of Schizophrenia

Sukanta Saha, David Chant, Joy Welham, John McGrath

National Trends in Statin Use by Coronary Heart Disease Risk Category

Jun Ma, Niraj L Sehgal, John Z Ayanian, Randall S Stafford

An Immune Basis for Malaria Protection by the Sickle Cell Trait

Thomas N Williams, Tabitha W Mwangi, David J Roberts, Neal D Alexander, David J Weatherall, Sammy Wambua, Moses Kortok, Robert W Snow, Kevin Marsh

Correspondence

Editors' Reply

Virginia Barbour, Barbara Cohen, Gavin Yamey

Association between Injections and HIV Incidence

Naveed Zafar Janjua, Khabir Ahmad, Arshad Altaf, Mohammad Imran Khan, Hasan Bin Hamza

Correction

Correction: Buruli Ulcer (M. ulcerans Infection): New Insights, New Hope for Disease Control

Paul D. R Johnson, Timothy Stinear, Pamela L. C Small, Gerd Pluschke, Richard W Merritt, Francoise Portaels, Kris Huygen, John A Hayman, Kingsley Asiedu